New hope for high-risk MDS: phase 3 trial of lisaftoclax combo launches
NCT ID NCT06641414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding lisaftoclax to standard azacitidine helps people with newly diagnosed higher-risk myelodysplastic syndrome (a serious blood cancer) live longer. About 490 participants worldwide will receive either the combo or a placebo plus azacitidine. The main goal is to see if the new combination improves overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77054, United States
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100033, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.